

BaxGen Therapeutics Inc.

50 Pheasant Run
Roslyn, NY 11576

Evrís Gavathíotis, PhD
T 646-2074712

www.baxgentherapeutics.com
egavathiotis@gmail.com

Industry: Pharma - Therapeutics

Management:

Evrís Gavathíotis, PhD
Founder, CEO/CSO
Professor, Biochemistry, Medicine,
Oncology, Co-leader Cancer
Therapeutics, Montefiore Einstein
Cancer Center

Seeking CEO, Head of R&D

Board: Seeking members

Scientific Advisory Board:

Marina Konopleva, MD, PhD
Director of Leukemia Program,
Montefiore Einstein Cancer Center
Professor of Medicine, Albert Einstein
College of Medicine

Amit Verma, MBBS

Director of Hemato-Oncology, Assoc.
Director of Translational Science,
Montefiore Einstein Cancer Center
Professor of Medicine at Montefiore
Einstein

Loren Walensky, MD, PhD

Professor of Pediatrics and Chemical
Biology, Dana Farber Cancer Institute,
Harvard Medical School

Finance:

Accounting / Tax: Seeking

Financing Sought: \$10M total
\$2.5M for IND-enabling studies,
operating costs and IP, \$7.5M for
Phase I

IP: Fox Rothschild LLP

Legal: Sioris Law Office

BaxGen Therapeutics

targeting apoptosis directly

**Business Description:**

BaxGen Therapeutics Inc. is a pioneering biotech company poised to revolutionize cancer treatment with its innovative approach focused on developing small molecules directly targeting the apoptosis pathway in cancer. The company leverages a robust platform built on deep insights into the apoptosis pathway, innovative structure-based and computational drug design methods, and biomarker-driven combination targeting strategies. The first product is BGT-001, a first-in-class small molecule activator of BAX, a novel target and a critical effector protein of apoptosis that has, until now, been deemed “undruggable”. BaxGen will address unmet medical needs across a spectrum of blood and solid tumor cancers, offering promising avenues for improved patient outcomes and transforming the landscape of cancer therapeutics.

Company Background:

The company was founded in 2024 by Prof. Evrís Gavathíotis, motivated by the impact of cancer on loved ones, with the aim of achieving breakthrough treatments that enhance patient outcomes and save lives. Prof. Gavathíotis is an innovative researcher (45 patents) in field of cell death mechanisms and cancer therapeutics with entrepreneurial expertise as co-founder of four biotech companies. He has led groundbreaking discoveries unraveling the complexities of the apoptosis pathway and identifying key molecular targets for therapeutic intervention that formed the basis of BaxGen Therapeutics.

Market Opportunity / Unmet Need:

The market opportunity for a first-in-class drug targeting apoptosis via BAX activation in acute myeloid leukemia (AML), other blood cancers and solid tumors such as colorectal, pancreatic, and NSCLC is substantial. By addressing unmet medical needs and offering a novel mechanism of action, such a drug has the potential to make a significant impact on patient care while capturing a meaningful share of the global oncology therapeutics market (> \$3 Billion).

Products/Services – Launched & Pipeline:

BaxGen's lead program, BGT-001, is currently in being advanced through CMC optimization and IND-enabling studies. It is expected to enter Phase I clinical studies in 12 months for the treatment of AML. Following success in AML, BGT-001 will be studied in a variety of other malignancies. BaxGen's pipeline extends to a range of innovative compounds tailored for the treatment of tumors, targeting additional apoptosis targets e.g. BAK, BCL-XL and non-oncological disease applications.

Commercial / Technical Milestones:

Achieved: incorporation, IP (four patent families, two granted patents (2023, 2024) and others advanced to application PCT stage), lead optimization. Pending: complete management team, additional IP, complete IND-enabling studies and IND approval (Q2 2025) complete Phase I studies (Q3, 2027).

Competition / Competitive Advantages:

BaxGen has a unique position with its pioneering strategy in the field of apoptosis-targeted cancer therapies. While other companies may have compounds and products that can potentially complement BaxGen's lead agent, none directly target the BAX protein, presenting a compelling opportunity to carve out a niche and establish itself as a leader.

Financial Forecast

BaxGen plans to scale up with non-dilutive federal funds (e.g. SBIR) to support IND/Phase I studies and seek partnerships to expand clinical trials of combinations with BGT-001 and leverage additional compounds in the pipeline.